From IND to PDUFA
Regulatory Writing
We take your medicinal product from pre-IND through approval
Investigational New Drug (IND) Application Documents
Investigator's Brochure
Clinical Study Protocols (including clinical trial design)
Informed Consent Forms
Pharmacology and Toxicology Information
General Investigational Plan
Annual Reports
Safety Reports
New Drug Application (NDA) Documents
Common Technical Document (CTD) Modules:
Module 2: Summaries
Quality Overall Summary
Nonclinical Overview and Summaries
Clinical Overview and Summaries
Module 3: Quality (in close collaboration with CMC experts)
Module 4: Nonclinical Study Reports
Module 5: Clinical Study Reports
Clinical Study Reports (CSRs)
Phase 1, 2, and 3 CSRs
Integrated Summary of Safety (ISS) (in collaboration with statisticians and programmers)
Integrated Summary of Efficacy (ISE) (in collaboration with statisticians and programmers)
Regulatory Correspondence
Responses to FDA Information Requests
Meeting Briefing Packages
Minutes from FDA Meetings
Product Labeling
Package Inserts
Medication Guides
Patient Information Leaflets
Risk Management Documents
Risk Evaluation and Mitigation Strategy (REMS)
Risk Management Plans
Periodic Safety Reports
Periodic Adverse Drug Experience Reports (PADERs)
Development Safety Update Reports (DSURs)
Special Designations and Expedited Programs
Orphan Drug Designation Requests
Fast Track Designation Requests
Breakthrough Therapy Designation Requests
Post-Marketing Documents
Annual Reports
Supplemental NDAs for new indications or formulations
Periodic Safety Update Reports (PSURs)
Advisory Committee Meeting Materials
Briefing Documents
Presentation Slides
Responses to Complete Response Letters
Addressing FDA's concerns and requests for additional information
Miscellaneous
Pharmacokinetic and pharmacodynamic data summaries
Drug-drug interaction studies reports
Bioequivalence study reports for generic small molecule drugs
Stability data summaries
Impurity profiles and related safety assessments